BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Carfilzomib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Carfilzomib\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04973605-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Carfilzomib: Phase 1/2 readout est. (NCT04973605)
DESCRIPTION:Carfilzomib\, phase 1/2\, Multiple Myeloma.\nStudy: A Phase 1b/
 2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinati
 ons With Dexamethasone Plus Carfilzomib\, Dexamethasone Plus Daratumumab\,
  and Dexamethasone Plus Pomalidomide in Multiple Myeloma\nEstimated primar
 y completion: November 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/carfilzomib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04973605
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06249282-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20261124
DTEND;VALUE=DATE:20261125
SUMMARY:Carfilzomib: Phase 1 readout est. (NCT06249282)
DESCRIPTION:Carfilzomib\, phase 1.\nStudy: Carfilzomib in Combination With 
 Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or
  Metastatic Non-small Cell Lung Cancer\nEstimated primary completion: 24 N
 ovember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/carfilz
 omib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06249282
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03989414-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Carfilzomib: Phase 1/2 readout est. (NCT03989414)
DESCRIPTION:Carfilzomib\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to 
 Determine the Recommended Dose and Regimen and to Evaluate the Safety and 
 Preliminary Efficacy of CC-92480 in Combination With Standard Treatments i
 n Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and New
 ly Diagnosed Multiple Myeloma (NDMM)\nEstimated primary completion: 30 Nov
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/carfilzom
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 3989414
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03729804-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20261228
DTEND;VALUE=DATE:20261229
SUMMARY:Carfilzomib: Phase 3 readout est. (NCT03729804)
DESCRIPTION:Carfilzomib\, phase 3\, Multiple Myeloma.\nStudy: Carfilzomib\,
  Lenalidomide\, and Dexamethasone Versus Bortezomib\, Lenalidomide and Dex
 amethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma
  (COBRA)\nEstimated primary completion: 28 December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/carfilzomib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT03729804
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04883242-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Carfilzomib: Phase 2 readout est. (NCT04883242)
DESCRIPTION:Carfilzomib\, phase 2\, Multiple Myeloma.\nStudy: Isatuximab\, 
 Carfilzomib\, Pomalidomide\, and Dexamethasone for the Treatment of Relaps
 ed or Refractory Multiple Myeloma\nEstimated primary completion: 31 Decemb
 er 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/carfilzomib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0488
 3242
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01863550-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Carfilzomib: Phase 3 readout est. (NCT01863550)
DESCRIPTION:Carfilzomib\, phase 3\, Multiple Myeloma.\nStudy: Bortezomib or
  Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With
  Newly Diagnosed Multiple Myeloma\nEstimated primary completion: 31 Decemb
 er 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/carfilzomib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0186
 3550
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04268498-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Carfilzomib: Phase 2 readout est. (NCT04268498)
DESCRIPTION:Carfilzomib\, phase 2\, Multiple Myeloma.\nStudy: A Study of Da
 ratumumab\, Carfilzomib\, Lenalidomide\, and Dexamethasone in Patients Wit
 h Newly-Diagnosed Multiple Myeloma\nEstimated primary completion: 1 Februa
 ry 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/carfilzomib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0426
 8498
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02343042-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Carfilzomib: Phase 1/2 readout est. (NCT02343042)
DESCRIPTION:Carfilzomib\, phase 1/2\, Multiple Myeloma.\nStudy: Selinexor a
 nd Backbone Treatments of Multiple Myeloma Patients\nEstimated primary com
 pletion: April 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 carfilzomib#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT02343042
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06356571-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Carfilzomib: Phase 2 readout est. (NCT06356571)
DESCRIPTION:Carfilzomib\, phase 2\, Multiple Myeloma.\nStudy: A Study to In
 vestigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib a
 nd Dexamethasone in Adult Participants With Relapsed and/or Refractory Mul
 tiple Myeloma\nEstimated primary completion: 1 April 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/carfilzomib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06356571
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06622005-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20270410
DTEND;VALUE=DATE:20270411
SUMMARY:Carfilzomib: Phase 1 readout est. (NCT06622005)
DESCRIPTION:Carfilzomib\, phase 1\, Multiple Myeloma.\nStudy: SX-682 in Com
 bination With Carfilzomib\, Daratumumab-Hyaluronidase\, and Dexamethasone 
 in Patients With Relapsed or Refractory Multiple Myeloma\nEstimated primar
 y completion: 10 April 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/carfilzomib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06622005
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04176718-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Carfilzomib: Phase 2 readout est. (NCT04176718)
DESCRIPTION:Carfilzomib\, phase 2\, Multiple Myeloma.\nStudy: Daratumumab\,
  Carfilzomib\, Pomalidomide\, Dexamethasone In MM\nEstimated primary compl
 etion: May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/carf
 ilzomib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04176718
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06627751-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Carfilzomib: Phase 2 readout est. (NCT06627751)
DESCRIPTION:Carfilzomib\, phase 2\, Multiple Myeloma.\nStudy: Mezigdomide\,
  Carfilzomib\, and Dexamethasone for the Treatment of Relapsed or Refracto
 ry Multiple Myeloma in Patients With Extramedullary Disease\nEstimated pri
 mary completion: 1 May 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/carfilzomib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06627751
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01297764-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Carfilzomib: Phase 1/2 readout est. (NCT01297764)
DESCRIPTION:Carfilzomib\, phase 1/2\, Multiple Myeloma.\nStudy: A Study of 
 Carfilzomib\, Lenalidomide\, Vorinostat\, and Dexamethasone in Relapsed an
 d/or Refractory Multiple Myeloma\nEstimated primary completion: June 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/carfilzomib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT01297764
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02899052-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Carfilzomib: Phase 2 readout est. (NCT02899052)
DESCRIPTION:Carfilzomib\, phase 2\, Multiple Myeloma.\nStudy: Study of Vene
 toclax in Combination With Carfilzomib and Dexamethasone in Participants W
 ith Relapsed or Refractory Multiple Myeloma (MM)\nEstimated primary comple
 tion: June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/carf
 ilzomib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT02899052
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06918990-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Carfilzomib: Phase 1 readout est. (NCT06918990)
DESCRIPTION:Carfilzomib\, phase 1.\nStudy: Treatment of Antibody-Mediated R
 ejection (ABMR) With CarBel\nEstimated primary completion: 30 June 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/carfilzomib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06918990
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05909826-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Carfilzomib: Phase 2 readout est. (NCT05909826)
DESCRIPTION:Carfilzomib\, phase 2\, Multiple Myeloma.\nStudy: Carfilzomib\,
  Oral Cyclophosphamide\, and Dexamethasone for RRMM\nEstimated primary com
 pletion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/carfilzomib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05909826
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07479979-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Carfilzomib: Phase 1/2 readout est. (NCT07479979)
DESCRIPTION:Carfilzomib\, phase 1/2\, Multiple Myeloma.\nStudy: Study of Se
 linexor With Carfilzomib\, Isatuximab and Dexamethasone for Patients With 
 Relapsed and/or Refractory Multiple Myeloma\nEstimated primary completion:
  July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/carfilzom
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7479979
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03556332-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Carfilzomib: Phase 2 readout est. (NCT03556332)
DESCRIPTION:Carfilzomib\, phase 2\, Multiple Myeloma.\nStudy: A Study of Ca
 rfilzomib\, Lenalidomide\, Dexamethasone and Daratumumab for Patients With
  Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Tr
 ansplantation\nEstimated primary completion: July 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/carfilzomib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT03556332
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03909412-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Carfilzomib: Phase 1 readout est. (NCT03909412)
DESCRIPTION:Carfilzomib\, phase 1\, Multiple Myeloma.\nStudy: Carfilzomib B
 ased Chemotherapy Mobilization for Autologous Stem Cell Transplants in Mul
 tiple Myeloma\nEstimated primary completion: August 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/carfilzomib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT03909412
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04096066-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Carfilzomib: Phase 3 readout est. (NCT04096066)
DESCRIPTION:Carfilzomib\, phase 3\, Multiple Myeloma.\nStudy: A Trial That 
 Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible fo
 r Transplant\nEstimated primary completion: 1 September 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/carfilzomib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT04096066
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03004287-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Carfilzomib: Phase 2 readout est. (NCT03004287)
DESCRIPTION:Carfilzomib\, phase 2\, Multiple Myeloma.\nStudy: 2015-12: A St
 udy Exploring the Use of Early and Late Consolidation/Maintenance Therapy\
 nEstimated primary completion: October 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/carfilzomib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT03004287
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04850599-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20271015
DTEND;VALUE=DATE:20271016
SUMMARY:Carfilzomib: Phase 2 readout est. (NCT04850599)
DESCRIPTION:Carfilzomib\, phase 2\, Multiple Myeloma.\nStudy: Isatuximab\, 
 Carfilzomib\, and Pomalidomide for the Treatment of Relapsed or Refractory
  Multiple Myeloma\nEstimated primary completion: 15 October 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/carfilzomib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04850599
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02659293-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Carfilzomib: Phase 3 readout est. (NCT02659293)
DESCRIPTION:Carfilzomib\, phase 3\, Multiple Myeloma.\nStudy: Trial of Carf
 ilzomib\, Lenalidomide\, Dexamethasone Versus Lenalidomide Alone After Ste
 m-cell Transplant for Multiple Myeloma\nEstimated primary completion: Nove
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/carfilzomi
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT02
 659293
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06409702-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Carfilzomib: Phase 4 readout est. (NCT06409702)
DESCRIPTION:Carfilzomib\, phase 4\, Multiple Myeloma.\nStudy: Treatment of 
 High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease D
 etection\nEstimated primary completion: 30 November 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/carfilzomib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06409702
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06158841-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Carfilzomib: Phase 3 readout est. (NCT06158841)
DESCRIPTION:Carfilzomib\, phase 3\, Multiple Myeloma.\nStudy: Study Assessi
 ng Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Avai
 lable Therapies in Adult Participants With Relapsed or Refractory Multiple
  Myeloma\nEstimated primary completion: December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/carfilzomib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06158841
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06615479-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Carfilzomib: Phase 3 readout est. (NCT06615479)
DESCRIPTION:Carfilzomib\, phase 3\, Multiple Myeloma.\nStudy: A Study to Co
 mpare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Ad
 ult Participants With Relapsed or Refractory and Lenalidomide-exposed Mult
 iple Myeloma (QUINTESSENTIAL-2)\nEstimated primary completion: 30 December
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/carfilzomib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT066154
 79
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05651932-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Carfilzomib: Phase 1 readout est. (NCT05651932)
DESCRIPTION:Carfilzomib\, phase 1\, Multiple Myeloma.\nStudy: A Study of an
  MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
 \nEstimated primary completion: 31 December 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/carfilzomib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05651932
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07652879-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Carfilzomib: Phase 2 readout est. (NCT07652879)
DESCRIPTION:Carfilzomib\, phase 2.\nStudy: KCD (Carfilzomib/Cyclophosphamid
 e/Dexamethasone) Regimen for the Treatment of Newly Diagnosed POEMS Syndro
 me\nEstimated primary completion: January 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/carfilzomib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07652879
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04661137-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Carfilzomib: Phase 2 readout est. (NCT04661137)
DESCRIPTION:Carfilzomib\, phase 2\, Multiple Myeloma.\nStudy: A Study of Se
 linexor\, in Combination With Carfilzomib\, Daratumumab or Pomalidomide in
  Patients With Multiple Myeloma\nEstimated primary completion: February 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/carfilzomib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT04661137
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06879379-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Carfilzomib: Phase 2/3 readout est. (NCT06879379)
DESCRIPTION:Carfilzomib\, phase 2/3\, Multiple Myeloma.\nStudy: KPD Consoli
 dation After ASCT in NDMM Patients\nEstimated primary completion: March 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/carfilzomib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06879379
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05137054-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20280325
DTEND;VALUE=DATE:20280326
SUMMARY:Carfilzomib: Phase 1 readout est. (NCT05137054)
DESCRIPTION:Carfilzomib\, phase 1\, Multiple Myeloma.\nStudy: A Study to Ex
 amine the Effects of Novel Therapy Linvoseltamab in Combination With Other
  Cancer Treatments for Adult Participants With Multiple Myeloma That is Re
 sistant to Current Standard of Care Treatments\nEstimated primary completi
 on: 25 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ca
 rfilzomib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05137054
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04263480-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Carfilzomib: Phase 2 readout est. (NCT04263480)
DESCRIPTION:Carfilzomib\, phase 2.\nStudy: Efficacy and Safety of Carfilzom
 ib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobu
 linemia\nEstimated primary completion: May 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/carfilzomib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT04263480
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05789303-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Carfilzomib: Phase 2 readout est. (NCT05789303)
DESCRIPTION:Carfilzomib\, phase 2\, Multiple Myeloma.\nStudy: Study of Bela
 ntamab Mafodotin With Carfilzomib\, Pomalidomide\, and Dexamethasone in Re
 lapsed Multiple Myeloma\nEstimated primary completion: 1 July 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/carfilzomib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05789303
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05434689-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Carfilzomib: Phase 1/2 readout est. (NCT05434689)
DESCRIPTION:Carfilzomib\, phase 1/2\, Multiple Myeloma.\nStudy: COMbination
  Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide\nEstimated
  primary completion: August 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/carfilzomib#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05434689
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05669989-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Carfilzomib: Phase 2 readout est. (NCT05669989)
DESCRIPTION:Carfilzomib\, phase 2\, Multiple Myeloma.\nStudy: International
  Treatment-extension Study in Adult Participants With Multiple Myeloma and
  Who Have Derived Clinical Benefit From Isatuximab\nEstimated primary comp
 letion: 30 November 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/carfilzomib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05669989
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07709884-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Carfilzomib: Phase 4 readout est. (NCT07709884)
DESCRIPTION:Carfilzomib\, phase 4\, Multiple Myeloma.\nStudy: A Single-cent
 er\, Prospective\, Single-arm Clinical Study Exploring the Treatment of Ne
 wly Diagnosed Multiple Myeloma Patients With t(11\;14) Suitable for Transp
 lantation Using the SonKRd Regimen\nEstimated primary completion: 31 Decem
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/carfilzomib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT077
 09884
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05438043-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Carfilzomib: Phase 3 readout est. (NCT05438043)
DESCRIPTION:Carfilzomib\, phase 3\, Multiple Myeloma.\nStudy: A Study of Da
 ratumumab\nEstimated primary completion: 31 January 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/carfilzomib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05438043
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07348393-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Carfilzomib: Phase 2 readout est. (NCT07348393)
DESCRIPTION:Carfilzomib\, phase 2\, Multiple Myeloma.\nStudy: A Phase 2\, S
 ingle Arm Multicenter\, Study Testing Mezigdomide\, Carfilzomib\, and Dexa
 methasone (480Kd) in Participants With Relapsed or Refractory Multiple Mye
 loma (RRMM)\nEstimated primary completion: February 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/carfilzomib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07348393
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05896228-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20290301
DTEND;VALUE=DATE:20290302
SUMMARY:Carfilzomib: Phase 2 readout est. (NCT05896228)
DESCRIPTION:Carfilzomib\, phase 2\, Multiple Myeloma.\nStudy: Iberdomide\, 
 Daratumumab\, Carfilzomib\, and Dexamethasone (Iber-KDd) in Patients With 
 Relapsed/Refractory Multiple Myeloma\nEstimated primary completion: 1 Marc
 h 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/carfilzomib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05896
 228
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04822337-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Carfilzomib: Phase 1/2 readout est. (NCT04822337)
DESCRIPTION:Carfilzomib\, phase 1/2\, Multiple Myeloma.\nStudy: Study of Ca
 rfilzomib\, Lenalidomide\, Dexamethasone and Belantamab Mafodotin in Multi
 ple Myeloma\nEstimated primary completion: April 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/carfilzomib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT04822337
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222761-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20290521
DTEND;VALUE=DATE:20290522
SUMMARY:Carfilzomib: Phase 3 readout est. (NCT07222761)
DESCRIPTION:Carfilzomib\, phase 3\, Multiple Myeloma.\nStudy: A Study to Co
 mpare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combinatio
 n Therapy With Standard-of-Care Combination Regimens in Adult Participants
  With Relapsed/Refractory Multiple Myeloma (RRMM)\nEstimated primary compl
 etion: 21 May 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/c
 arfilzomib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07222761
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03948035-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Carfilzomib: Phase 3 readout est. (NCT03948035)
DESCRIPTION:Carfilzomib\, phase 3\, Multiple Myeloma.\nStudy: Elotuzumab in
  Combination With Carfilzomib\, Lenalidomide and Dexamethasone (E-KRd) Ver
 sus KRd in MM\nEstimated primary completion: August 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/carfilzomib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT03948035
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07715903-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Carfilzomib: Phase 1 readout est. (NCT07715903)
DESCRIPTION:Carfilzomib\, phase 1.\nStudy: Hepatic Artery Infusion of Carfi
 lzomib in Participants With Liver Metastatic Disease Previously Treated Wi
 th Hepatic Artery Infusion Pump Therapy\nEstimated primary completion: 31 
 December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/carfil
 zomib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07715903
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227311-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20300830
DTEND;VALUE=DATE:20300831
SUMMARY:Carfilzomib: Phase 2 readout est. (NCT07227311)
DESCRIPTION:Carfilzomib\, phase 2\, Multiple Myeloma.\nStudy: A Study to Ev
 aluate the Efficacy and Safety of Belantamab Mafodotin in Combination With
  Standard of Care in Participants With Relapsed-Refractory Multiple Myelom
 a (RRMM)\nEstimated primary completion: 30 August 2030. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/carfilzomib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07227311
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04513639-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20310601
DTEND;VALUE=DATE:20310602
SUMMARY:Carfilzomib: Phase 2/3 readout est. (NCT04513639)
DESCRIPTION:Carfilzomib\, phase 2/3\, Multiple Myeloma.\nStudy: The Relapse
  from MRD Negativity As Indication for Treatment (REMNANT) Study\nEstimate
 d primary completion: 1 June 2031. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/carfilzomib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT04513639
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07605416-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20321106
DTEND;VALUE=DATE:20321107
SUMMARY:Carfilzomib: Phase 2 readout est. (NCT07605416)
DESCRIPTION:Carfilzomib\, phase 2.\nStudy: Testing an Experimental Approach
  to Treat Patients With Plasma Cell Leukemia\, The QUANTUM Trial\nEstimate
 d primary completion: 6 November 2032. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/carfilzomib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07605416
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06892522-2284@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20351231
DTEND;VALUE=DATE:20360101
SUMMARY:Carfilzomib: Phase 1/2 readout est. (NCT06892522)
DESCRIPTION:Carfilzomib\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to 
 Assess Change in Disease Activity and Adverse Events (AE)s in Adult Partic
 ipants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Ant
 ibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations\nE
 stimated primary completion: December 2035. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/carfilzomib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06892522
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
